KR20070101843A - 확장기 기능장애 또는 확장기 심부전의 예방 또는 치료를위한 레닌 억제제의 용도 - Google Patents

확장기 기능장애 또는 확장기 심부전의 예방 또는 치료를위한 레닌 억제제의 용도 Download PDF

Info

Publication number
KR20070101843A
KR20070101843A KR1020077007885A KR20077007885A KR20070101843A KR 20070101843 A KR20070101843 A KR 20070101843A KR 1020077007885 A KR1020077007885 A KR 1020077007885A KR 20077007885 A KR20077007885 A KR 20077007885A KR 20070101843 A KR20070101843 A KR 20070101843A
Authority
KR
South Korea
Prior art keywords
alkyl
pharmaceutically acceptable
alkoxy
compound
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020077007885A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 루이스 펠드만
프리드리히 카메론 루프트
도미니크 니콜라스 뮐러
랜디 리 웹
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35789048&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20070101843(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20070101843A publication Critical patent/KR20070101843A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
KR1020077007885A 2004-10-08 2005-10-06 확장기 기능장애 또는 확장기 심부전의 예방 또는 치료를위한 레닌 억제제의 용도 Ceased KR20070101843A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US61720204P 2004-10-08 2004-10-08
US60/617,202 2004-10-08
US66789905P 2005-04-01 2005-04-01
US60/667,899 2005-04-01

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020137010963A Division KR20130048281A (ko) 2004-10-08 2005-10-06 확장기 기능장애 또는 확장기 심부전의 예방 또는 치료를 위한 레닌 억제제의 용도

Publications (1)

Publication Number Publication Date
KR20070101843A true KR20070101843A (ko) 2007-10-17

Family

ID=35789048

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020077007885A Ceased KR20070101843A (ko) 2004-10-08 2005-10-06 확장기 기능장애 또는 확장기 심부전의 예방 또는 치료를위한 레닌 억제제의 용도
KR1020137010963A Withdrawn KR20130048281A (ko) 2004-10-08 2005-10-06 확장기 기능장애 또는 확장기 심부전의 예방 또는 치료를 위한 레닌 억제제의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020137010963A Withdrawn KR20130048281A (ko) 2004-10-08 2005-10-06 확장기 기능장애 또는 확장기 심부전의 예방 또는 치료를 위한 레닌 억제제의 용도

Country Status (15)

Country Link
US (2) US20080085914A1 (enExample)
EP (2) EP2248520A3 (enExample)
JP (1) JP2008515903A (enExample)
KR (2) KR20070101843A (enExample)
CN (1) CN101102755B (enExample)
AT (1) ATE551052T1 (enExample)
AU (2) AU2005294318A1 (enExample)
BR (1) BRPI0516128A (enExample)
CA (1) CA2580862A1 (enExample)
ES (1) ES2384637T3 (enExample)
MX (1) MX2007004020A (enExample)
PL (1) PL1799199T3 (enExample)
PT (1) PT1799199E (enExample)
RU (1) RU2407523C2 (enExample)
WO (1) WO2006041974A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1972335A1 (en) * 2007-03-23 2008-09-24 Krka Solid dosage forms comprising aliskiren and pharmaceutically acceptable salts thereof
KR20090127174A (ko) 2007-03-27 2009-12-09 칼피스가부시키가이샤 심부전 예방제
AR066168A1 (es) * 2007-09-28 2009-07-29 Novartis Ag Formulaciones galenicas de compuestos organicos
JP2010540548A (ja) * 2007-09-28 2010-12-24 ノバルティス アーゲー アリスキレンとバルサルタンの医薬組み合わせ剤
MX2011007779A (es) * 2009-01-28 2011-08-12 Novartis Ag Formulaciones galenicas de compuestos organicos.
EP2340820A1 (en) * 2009-12-16 2011-07-06 KRKA, tovarna zdravil, d.d., Novo mesto Moisture-activated granulation process
EP2216020A1 (en) * 2009-02-05 2010-08-11 KRKA, tovarna zdravil, d.d., Novo mesto Moisture-activated granulation process
WO2010089105A2 (en) * 2009-02-05 2010-08-12 Krka, Tovarna Zdravil, D.D., Novo Mesto Moisture-activated granulation process
US20120107397A1 (en) * 2009-07-03 2012-05-03 Hetero Research Foundation Pharmaceutical compositions of valsartan
US20110268797A1 (en) * 2010-04-30 2011-11-03 Sanovel IIac Sanayi Ve Ticaret Anonim Sirketi Multicoated aliskiren formulations
FR2961105B1 (fr) * 2010-06-15 2013-02-08 Servier Lab Utilisation de l'association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion de l'angiotensine pour le traitement de l'insuffisance cardiaque

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
ES2142789T3 (es) 1989-06-14 2000-05-01 Smithkline Beecham Corp Acidos imidazolil-alquenoicos.
IL97219A (en) 1990-02-19 1995-12-08 Ciba Geigy Ag Biphenyl substituted aliphatic amino compounds process for their preparation and pharmaceutical compositions containing them
PT97078B (pt) 1990-03-20 1997-07-31 Sanofi Sa Processo para a preparacao de derivados heterociclicos n-substituidos e de composicoes farmaceuticas que os contem
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
RU2147875C1 (ru) * 1990-05-11 2000-04-27 Пфайзер Инк. Способ и композиция для снижения кровяного давления и лечения застойной сердечной недостаточности у млекопитающего
CA2229000C (en) 1991-02-21 2002-04-09 Sankyo Company, Limited 1-biphenylimidazole derivatives, their preparation and their therapeutic use
DE4121975A1 (de) 1991-07-03 1993-01-07 Basf Ag Thermoplastische formmassen auf der basis von polycarbonaten, styrol/acrylnitril-polymerisaten und polyolefinen
TW226375B (enExample) 1991-10-24 1994-07-11 American Home Prod
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
US6376672B1 (en) 1999-04-27 2002-04-23 Hoffmann-La Roche Inc. Naphthalenylmethoxypiperidines as renin inhibitors
US6197959B1 (en) 1999-04-27 2001-03-06 Hoffmann-La Roche Inc. Piperidine derivatives
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
AU2002226365A1 (en) * 2000-12-01 2002-06-11 Novartis Ag Combinations of an angiotensin receptor antagonist and an anti-hypertensive drug or a statin, for the treatment of sexual dysfunction
US7019010B2 (en) * 2001-09-27 2006-03-28 Novertis Ag Combinations
GB0212412D0 (en) * 2002-05-29 2002-07-10 Novartis Ag Combination of organic compounds
GB0212410D0 (en) * 2002-05-29 2002-07-10 Novartis Ag Organic compounds
JP2005537822A (ja) * 2002-06-28 2005-12-15 ノバルティス アクチエンゲゼルシャフト 有機化合物の使用
DE602004022704D1 (de) * 2003-11-26 2009-10-01 Novartis Ag 4-phenylpiperidinderivate als renininhibitoren
CN1882528A (zh) * 2003-11-26 2006-12-20 诺瓦提斯公司 有机化合物
GB0327839D0 (en) * 2003-12-01 2003-12-31 Novartis Ag Organic compounds
PE20050596A1 (es) * 2003-12-19 2005-10-18 Novartis Ag Microemulsion que comprende un inhibidor renina
MY146830A (en) * 2005-02-11 2012-09-28 Novartis Ag Combination of organic compounds

Also Published As

Publication number Publication date
EP1799199B1 (en) 2012-03-28
JP2008515903A (ja) 2008-05-15
CN101102755A (zh) 2008-01-09
US20080085914A1 (en) 2008-04-10
BRPI0516128A (pt) 2008-08-26
MX2007004020A (es) 2007-05-24
AU2010200833A1 (en) 2010-04-01
PL1799199T3 (pl) 2012-09-28
RU2007116863A (ru) 2008-11-20
CN101102755B (zh) 2013-01-02
EP1799199A1 (en) 2007-06-27
US20130196977A1 (en) 2013-08-01
EP2248520A3 (en) 2010-11-17
EP2248520A2 (en) 2010-11-10
KR20130048281A (ko) 2013-05-09
RU2407523C2 (ru) 2010-12-27
AU2005294318A1 (en) 2006-04-20
CA2580862A1 (en) 2006-04-20
AU2010200833B2 (en) 2011-07-14
ES2384637T3 (es) 2012-07-10
WO2006041974A1 (en) 2006-04-20
PT1799199E (pt) 2012-07-03
ATE551052T1 (de) 2012-04-15

Similar Documents

Publication Publication Date Title
AU2010200833B2 (en) Use of renin inhibitors for the prevention or treatment of diastolic dysfunction or diastolic heart failure
AU2006212772B2 (en) Combination of organic compounds
JP6373931B2 (ja) 循環器系疾患のためのレニン阻害剤を含む相乗的組合せ剤
NZ536555A (en) Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
KR20080000624A (ko) 아테롬성동맥경화증의 치료 방법
US20080261958A1 (en) Combination of Organic Compounds
KR20080108156A (ko) 유기 화합물의 조합물
US20100292335A1 (en) Use of organic compounds
AU2011236117A1 (en) Use of renin inhibitors for the prevention or treatment of diastolic dysfunction or diastolic heart failure
CN101151027A (zh) 有机化合物的组合
MX2007009663A (en) Combination of organic compounds

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20070406

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20101005

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20120607

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20121231

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20120607

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20130401

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20121231

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20130502

Appeal identifier: 2013101002464

Request date: 20130401

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20130429

J121 Written withdrawal of request for trial
PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20130502

PJ1201 Withdrawal of trial

Patent event code: PJ12011R01D

Patent event date: 20130502

Comment text: Written Withdrawal of Request for Trial

Appeal identifier: 2013101002464

Request date: 20130401

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20130502

WITB Written withdrawal of application
J2X1 Appeal (before the patent court)

Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL

PJ2001 Appeal

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20150709

Appeal identifier: 2015201003832

Request date: 20150615

PJ1302 Judgment (patent court)

Patent event date: 20150731

Comment text: Written Judgment (Patent Court)

Patent event code: PJ13021S01D

Request date: 20150615

Decision date: 20150709

Appeal identifier: 2015201003832

Appeal kind category: Appeal against decision to decline refusal